Compare CYRX & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYRX | CSTL |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | 1100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 774.7M | 722.8M |
| IPO Year | 2008 | 2019 |
| Metric | CYRX | CSTL |
|---|---|---|
| Price | $16.92 | $34.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $13.31 | ★ $45.50 |
| AVG Volume (30 Days) | ★ 527.4K | 476.5K |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $176,177,000.00 | ★ $344,229,000.00 |
| Revenue This Year | $11.06 | $2.42 |
| Revenue Next Year | $8.45 | $12.69 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $7.61 | $17.72 |
| 52 Week High | $16.89 | $44.28 |
| Indicator | CYRX | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 65.07 | 71.82 |
| Support Level | $14.55 | $22.88 |
| Resistance Level | N/A | $41.55 |
| Average True Range (ATR) | 0.62 | 1.72 |
| MACD | 0.19 | 0.13 |
| Stochastic Oscillator | 98.61 | 98.61 |
CryoPort Inc is a provider of integrated, temperature-controlled supply chain solutions for the life sciences industry, with a focus on supporting the cell and gene therapy market. The company provides services such as temperature-controlled logistics, biostorage, bioservices, cryopreservation solutions, and cryogenic systems manufacturing. It operates through two reportable segments: Life Sciences Services and Life Sciences Products. It generates the majority of its revenue from the Life Sciences Services segment.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.